SpectraCure (SPEC) Stock Overview
Engages in the development of cancer treatment system. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SPEC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
SpectraCure AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.43 |
| 52 Week High | SEK 5.11 |
| 52 Week Low | SEK 0.31 |
| Beta | 0.37 |
| 1 Month Change | -48.19% |
| 3 Month Change | -76.06% |
| 1 Year Change | -82.70% |
| 3 Year Change | -94.59% |
| 5 Year Change | -97.31% |
| Change since IPO | -76.76% |
Recent News & Updates
Recent updates
SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans
Jul 31
We're Hopeful That SpectraCure (STO:SPEC) Will Use Its Cash Wisely
Feb 23We're Not Very Worried About SpectraCure's (STO:SPEC) Cash Burn Rate
Nov 09Companies Like SpectraCure (STO:SPEC) Are In A Position To Invest In Growth
Jul 27Companies Like SpectraCure (STO:SPEC) Are In A Position To Invest In Growth
Mar 09SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans
Nov 08SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans
Jul 26We Think SpectraCure (STO:SPEC) Can Afford To Drive Business Growth
Mar 19Here's Why We're Not Too Worried About SpectraCure's (STO:SPEC) Cash Burn Situation
Nov 16We Think SpectraCure (STO:SPEC) Can Easily Afford To Drive Business Growth
Aug 03We're Not Worried About SpectraCure's (STO:SPEC) Cash Burn
Apr 16Companies Like SpectraCure (STO:SPEC) Can Afford To Invest In Growth
Jan 01Shareholder Returns
| SPEC | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -27.0% | 1.2% | 1.2% |
| 1Y | -82.7% | -9.2% | -3.5% |
Return vs Industry: SPEC underperformed the Swedish Medical Equipment industry which returned -9% over the past year.
Return vs Market: SPEC underperformed the Swedish Market which returned -3.5% over the past year.
Price Volatility
| SPEC volatility | |
|---|---|
| SPEC Average Weekly Movement | 40.6% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in SE Market | 13.4% |
| 10% least volatile stocks in SE Market | 4.1% |
Stable Share Price: SPEC's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: SPEC's weekly volatility has increased from 29% to 41% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 16 | Masoud Khayyami | www.spectracure.com |
SpectraCure AB (publ) engages in the development of cancer treatment system. It develops Q-PRO, a laser device; and IDOSE software with interstitial photodynamic therapy system for the treatment of prostate cancer. The company was incorporated in 2003 and is based in Lund, Sweden.
SpectraCure AB (publ) Fundamentals Summary
| SPEC fundamental statistics | |
|---|---|
| Market cap | SEK 41.77m |
| Earnings (TTM) | -SEK 23.33m |
| Revenue (TTM) | n/a |
Is SPEC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPEC income statement (TTM) | |
|---|---|
| Revenue | -SEK 263.00k |
| Cost of Revenue | -SEK 9.69m |
| Gross Profit | SEK 9.43m |
| Other Expenses | SEK 32.76m |
| Earnings | -SEK 23.33m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | -3,584.03% |
| Net Profit Margin | 8,872.24% |
| Debt/Equity Ratio | 0% |
How did SPEC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/07 18:49 |
| End of Day Share Price | 2025/06/05 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SpectraCure AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Markus Augustsson | Carlsquare AB |